Biological Susceptibility of Patients with Schizophrenia to Metabolic Syndrome: A Review.

IF 1.3 Q3 PSYCHIATRY

Alpha psychiatry Pub Date : 2025-04-22 eCollection Date: 2025-04-01 DOI:10.31083/AP39896

Jun Ma, Zhengyuan Huang, Jing Chen, Gaohua Wang

{"title":"Biological Susceptibility of Patients with Schizophrenia to Metabolic Syndrome: A Review.","authors":"Jun Ma, Zhengyuan Huang, Jing Chen, Gaohua Wang","doi":"10.31083/AP39896","DOIUrl":null,"url":null,"abstract":"<p><p>Schizophrenia (SCZ) is a debilitating, chronic mental disorder with an elusive etiology that significantly impacts the life expectancy of affected individuals. Metabolic syndrome (MetS) is a condition characterized by a combination of factors that increase the risk of cardiovascular diseases. MetS is more prevalent in individuals with SCZ and is a major factor that contributes to their reduced lifespan. This review scrutinizes the biological factors that predispose patients with SCZ to MetS, among which, genetic predisposition, dietary and lifestyle modifications, and the use of antipsychotic drugs (APs) play a significant role. The metabolic side effects of APs have been well studied. While studies have shed light on potential interventions to manage MetS in patients with SCZ, identifying precise biological targets to treat SCZ remains challenging. Therefore, further studies are warranted to enhance our comprehension of the intricate mechanisms underlying the susceptibility of patients with SCZ to MetS. These studies will be crucial in developing effective, targeted therapeutic strategies to treat MetS in this vulnerable population.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"26 2","pages":"39896"},"PeriodicalIF":1.3000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059745/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alpha psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31083/AP39896","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Schizophrenia (SCZ) is a debilitating, chronic mental disorder with an elusive etiology that significantly impacts the life expectancy of affected individuals. Metabolic syndrome (MetS) is a condition characterized by a combination of factors that increase the risk of cardiovascular diseases. MetS is more prevalent in individuals with SCZ and is a major factor that contributes to their reduced lifespan. This review scrutinizes the biological factors that predispose patients with SCZ to MetS, among which, genetic predisposition, dietary and lifestyle modifications, and the use of antipsychotic drugs (APs) play a significant role. The metabolic side effects of APs have been well studied. While studies have shed light on potential interventions to manage MetS in patients with SCZ, identifying precise biological targets to treat SCZ remains challenging. Therefore, further studies are warranted to enhance our comprehension of the intricate mechanisms underlying the susceptibility of patients with SCZ to MetS. These studies will be crucial in developing effective, targeted therapeutic strategies to treat MetS in this vulnerable population.

查看原文本刊更多论文

精神分裂症患者对代谢综合征的生物学易感性：综述。

精神分裂症（SCZ）是一种使人衰弱的慢性精神障碍，其病因不明，严重影响患者的预期寿命。代谢综合征（MetS）是一种以增加心血管疾病风险的多种因素为特征的疾病。MetS在SCZ患者中更为普遍，是导致他们寿命缩短的主要因素。本文综述了SCZ患者易患MetS的生物学因素，其中遗传易感、饮食和生活方式改变以及抗精神病药物（APs）的使用发挥了重要作用。APs的代谢副作用已经得到了很好的研究。虽然研究已经阐明了潜在的干预措施来管理SCZ患者的MetS，但确定治疗SCZ的精确生物学靶点仍然具有挑战性。因此，需要进一步的研究来加强我们对SCZ患者对MetS易感性的复杂机制的理解。这些研究对于开发有效的、有针对性的治疗策略来治疗这些易感人群的MetS至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alpha psychiatry

自引率

0.00%

发文量